-
Howson introduced first in class oral antifellar drugs
Time of Update: 2021-03-07
Scynexis has submitted to the FDA a listing application for Ibrexafungerp oral preparations for the treatment of VVV candida disease (vaginal yeast infection), with PDUFA scheduled for approval on June 1, 2021.
-
Koren, Yangzijiang... 57 new drugs reported clinically! Zhengda Qing the first inhaler class 1 new drug debut, Qilu's first oral dissolved membrane came
Time of Update: 2021-03-06
(2020.12.26-2021.1.8) New drug listing application review status update domestic class 1 new drug Sovantini capsule was approved for market, the product is and Huang Pharmaceutical independently developed a new oral tyrosine kinase inhibitor, with anti-angiogenesic and immunomodulation dual activity.
-
New drug for plate plate plate reduction! The second generation of oral platelet-promoting
Time of Update: 2021-03-05
January 25, 2021 // -- Swedish pharmaceutical company Swedish Orphan Biovitrum AB (SOBI) recently announced that the European Commission (EC) has approved the expansion of the scope of doptelet (avatrombopag) for the treatment of primary chronic
-
Gilead's oral JAK1 inhibitor Jyseleca is available in Japan
Time of Update: 2021-03-05
an effect on sperm parameters and are expected to release top-line results in the first half of 2021. In addition, the FDA has expressed concern about the overall benefit/risk status of high doses of Jyseleca (200 mg). Jyseleca's
-
New anti-inflammatory drugs! AbbVie oral JAK1 inhibitor Rinvoq has been approved by the European Union to treat 2 new rheumatoids!
Time of Update: 2021-03-04
studies, Rinvoq reached the primary endpoint of the ACR20 response compared to a placebo. , 15 mg doses of Rinvoq and Adamo monoantigen showed non-poor effectiveness in treating the ACR20 response at week 12. patients treated with Rinvoq
-
First lupus nephritis (LN) oral drug! Lupkynis, the best-in-class calcium-adjusted neurophosphatase inhibitor, has been approved by the FDA!
Time of Update: 2021-03-04
recently, the company announced that the U.S. Food and Drug Administration (FDA) has approved Lupkynis (voclosporin), a joint background immunosuppressive therapy for the treatment of active lupus nephritis (LN) adult patients.
-
J dental Res: Effects of oral microorganisms on physical health
Time of Update: 2021-02-28
February 9, 2021 /--- Healthy mouth includes not only clean teeth and hard gums, but also flora living in a blood vessel-rich environment that keeps organisms in constant contact with immune system cells and proteins.
-
The new partner will test oral yew alcohol
Time of Update: 2021-02-26
Athenex, Cancer Research UK's Portfolio Alliance and the NIHR Clinical Research Network Industry Alliance have announced a partnership to test chemotherapy drugs that can be oral in early clinical trials.
-
AP-T: Comparison of direct oral anticoagulants and vitamin K antagonists in the risk of bleeding in the upper digestive tract
Time of Update: 2021-02-26
in order to compare the effects and side effects of new drugs and huafalin, this study analyzed the epidemiology and outcome of upper digestive tract bleeding (UGIB) caused by oral anticoagulant therapy.
-
RNAi therapy, which significantly inhibits activity in hepatitis B disease for 1 year after suspension, released the latest results
Time of Update: 2021-02-24
Retrieved November 16, 2020, from [2] HBV RNAi inhibitor RG6346 in Phase 1b-2a trial was safe, well-tolerated, and resulted in substantial and durable reductions in serum HBsAg levels.
-
Antisant oligonucleotide therapy reduces "bad" cholesterol by 70% showing the likelihood of oral dosing
Time of Update: 2021-02-24
data from these studies are very encouraging and demonstrate that ION449 has the potential to 'best-in-class' to reduce LDL-C for the treatment of high-cholesterol patients at risk of cardiovascular disease.
-
The world's first oral PI3K/CK1 inhibitor once a day has been approved by the FDA for the treatment of lymphoma
Time of Update: 2021-02-24
MZL is generally considered a chronic incurable disease, with about 8,200 newly diagnosed patients in the United States each year.
-
Behavioural Brain Research: Male Morality? Relationship between sex, oral contraceptives and underlying testosterone levels and ethical decision-making
Time of Update: 2021-02-23
addition to evaluating endogenetic testosterone, this paper investigates the role of sex and the relationship between the use of hormonal contraceptives and ethical decision-making.
-
Novo Nord developed oral Somaglutide to target patients with diabetic nephropathy
Time of Update: 2021-02-22
The trial data showed that for people with type 2 diabetes and renal damage, the oral preparation of its GLP-1 similar somalutide provided better than HbA1c and reduced the weight of the placebo, Novo Nord said.
-
GSK and Pfizer invested more than $50 million in oral integrated products
Time of Update: 2021-02-21
invested a foreign investment. Praveen Tipirneni says they hope to emulate Nimbus, which is part of a partnership with Schr Dinger. This spring, Nimbus Pharmaceuticals sold the ACC (acetyl coenzyme A carbohydrase) inhibitor program to Gilead Sciences
-
The function claims to classify the Japanese health food market, the whole intestine, anti-obesity, oral health scale expanded
Time of Update: 2021-02-19
5th "joints, anti-inflammation" market size: 760 billion yen main raw materials: amino glucose, cartilage sulfate, MSM , TYPE II collagen, protein polysaccharides, etc.
-
Protocols to Study the Physiology of Oral Biofilms
Time of Update: 2021-02-19
In this chapter, we use oral streptococci as examples for studying the physiology of oral biofilms.
-
The Oral Microbiota: General Overview, Taxonomy, and Nucleic Acid Techniques
Time of Update: 2021-02-19
Over 800 bacterial distinct species-level taxa have been detected in the oral cavity and recent studies using high-throughput technology suggest that the breadth of bacterial diversity can be much larger.
-
Oral Bacterial Genome Sequencing Using the High-Throughput Roche Genome Sequencer FLX System
Time of Update: 2021-02-17
For over 30 years, the chain termination method ofDNA sequencing (commonly known as Sanger sequencing) has been the mainstay of any DNA sequencing project.
-
New anti-inflammatory drugs! The FDA grants oral JAK/SYK dual-acting inhibitor ASN002 to treat the rapid pass of adiotic dermatitis:
Time of Update: 2021-02-17
the importance of accelerating the development of new drugs to treat challenging skin/inflammatory diseases that have a significant impact on patient life." We look forward to interacting well with the FDA throughout the development of ASN002 and accelerating
